InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,292.63
(
-0.23%
)
US TECH 100
18,314.75
(
-0.02%
)
Dow Jones
38,763.54
(
-0.78%
)
Brent Oil
84.20
(
1.64%
)
Bitcoin
68,149.01
(
-1.79%
)
Post# of 251948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119700
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171496

Saturday, 12/21/2013 6:37:34 PM

Saturday, December 21, 2013 6:37:34 PM

Post# of 251948
Copy editor needed immediately:

http://www.bizjournals.com/boston/blog/bioflash/2013/12/gilead-says-it-will-target-the-same.html

Gilead said today that based on promising data from a late-stage study of its drug, Sovaldi, it plans to apply for U.S. approval by the end of March for the drug as part of a regiment to treat hepatitis C genotype 1…

… Enanta’s stock fell double digits today on the news coming out of Gilead…

…Enanta is still the most successful of all the local biotechs that went public in 2013, with its stock price more than doubling since its March IPO.

At least the final paragraph is error-free, LOL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up